{"entity":{"id":"james-brenton","kind":"person","name":"James Brenton","aka":[],"tldr":"Cambridge medical oncologist and Interim Deputy Director of the CRUK Cambridge Institute, a leader in ovarian cancer genomics and ctDNA monitoring.","summary":"James Brenton is Interim Deputy Director and a Senior Group Leader at the Cancer Research UK Cambridge Institute, and a consultant medical oncologist at Cambridge University Hospitals. His research focuses on the genomics and evolution of high-grade serous ovarian cancer and on circulating tumour DNA as a tool for treatment monitoring. He leads the ovarian cancer programme within the CRUK Cambridge Centre.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/James_D._Brenton","links":[{"label":"Institution profile","url":"https://www.cruk.cam.ac.uk/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brenton+JD%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","ovarian cancer","cancer genomics"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cruk-cambridge-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["plos-medicine"],"dependsOn":[],"notes":[],"role":"Interim Deputy Director","institutionId":"cruk-cambridge-centre","specialisms":["Ovarian cancer","Cancer genomics","Circulating tumour DNA"],"profiles":[{"label":"Institution profile","url":"https://www.cruk.cam.ac.uk/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Brenton+JD%5BAuthor%5D"}],"papers":[{"title":"Copy number signatures and mutational processes in ovarian carcinoma","journal":"Nature Genetics","year":2018,"doi":"10.1038/s41588-018-0179-8"},{"title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","journal":"Nature Reviews Cancer","year":2017,"doi":"10.1038/nrc.2017.7"},{"title":"Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study","journal":"PLOS Medicine","year":2016,"doi":"10.1371/journal.pmed.1002198"}],"orcid":"0000-0002-5738-6683"},"route":"/people/james-brenton/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"institution":[{"id":"cruk-cambridge-centre","kind":"institution","name":"Cancer Research UK Cambridge Centre / CRUK Cambridge Institute","route":"/institutions/cruk-cambridge-centre/"}],"journal":[{"id":"plos-medicine","kind":"journal","name":"PLOS Medicine","route":"/journals/plos-medicine/"}]}}